期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
血管生成相关分子在静脉内平滑肌瘤中的表达特征及其诊断价值
1
作者 孙利娟 周峰 +3 位作者 chitapa benjoed 朱长焜 吕卫国 李阳 《中华医学杂志》 CAS CSCD 北大核心 2022年第26期2005-2010,共6页
目的分析静脉内平滑肌瘤(IVL)患者的临床病理特征,探讨血管生成相关分子在IVL中的表达特点及诊断价值。方法回顾性分析浙江大学医学院附属妇产科医院2013年1月至2021年4月收治的40例IVL患者的临床病理资料,Log-rank检验比较不同特征患... 目的分析静脉内平滑肌瘤(IVL)患者的临床病理特征,探讨血管生成相关分子在IVL中的表达特点及诊断价值。方法回顾性分析浙江大学医学院附属妇产科医院2013年1月至2021年4月收治的40例IVL患者的临床病理资料,Log-rank检验比较不同特征患者的无复发生存(RFS)率的差异。对10个血管生成相关分子进行免疫组织化学(IHC)染色,分析其在IVL中的表达特点,计算表达率高的分子诊断IVL的灵敏度和特异度,绘制受试者工作特征(ROC)曲线,并计算ROC曲线下面积(AUC),评估诊断价值。结果 40例IVL患者年龄[M(Q1,Q3)]为47(43,50)岁,临床表现不典型,术前超声诊断准确率为12.5%(5/40),CT和(或)磁共振成像(MRI)诊断准确率为26.7%(8/30),术中冰冻切片诊断准确率为30.0%(12/40)。IVL总体复发率为10.0%(4/40)。Log-rank检验结果显示,既往有剖宫产史的IVL患者的累积RFS率(40.9%)低于无剖宫产史者(96.4%)(P<0.05);中位RFS时间短于无剖宫产史者(16.4比22.2个月)。肾上腺髓质素(ADM)、成纤维细胞生长因子受体1(FGFR1)、血管内皮生长因子受体3(VEGFR3)和血管生成素受体酪氨酸激酶受体1(TIE1)在IVL中的总体阳性率分别为65.0%(26/40)、75.0%(30/40)、57.5%(23/40)和50.0%(20/40)。肿瘤最大径>5 cm者FGFR1表达强度和阳性率高于肿瘤最大径<5 cm者(P<0.05)。绘制ROC曲线发现,FGFR1联合ADM、VEGFR3和TIE1诊断IVL的AUC为0.876(95%CI:0.788~0.964,P<0.001)。结论 IVL临床表现无特异性,既往有剖宫产史者累积RFS率低,复发间隔较短,影像学及冰冻切片诊断率低。FGFR1与ADM、VEGFR3、TIE1在IVL中均呈高表达,四者联合应用诊断IVL的效能高于影像学及经典的血管内皮标志物的诊断水平。 展开更多
关键词 平滑肌瘤病 血管生成因子 免疫组织化学 成纤维细胞生长因子受体1
原文传递
Evaluation and simplification of risk factors in FIGO 2000 scoring system for gestational trophoblastic neoplasia:a 19-year retrospective analysis 被引量:1
2
作者 Yang WENG Yuanyuan LIU +5 位作者 chitapa benjoed Xiaodong WU Sangsang TANG Xiao LI Xing XIE Weiguo LU 《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》 SCIE CAS CSCD 2022年第3期218-229,共12页
Objective The International Federation of Gynecology and Obstetrics(FIGO)2000 scoring system classifies gestational trophoblastic neoplasia(GTN)patients into low-and high-risk groups,so that single-or multi-agent chem... Objective The International Federation of Gynecology and Obstetrics(FIGO)2000 scoring system classifies gestational trophoblastic neoplasia(GTN)patients into low-and high-risk groups,so that single-or multi-agent chemotherapy can be administered accordingly.However,a number of FIGO-defined low-risk patients still exhibit resistance to single-agent regimens,and the risk factors currently adopted in the FIGO scoring system possess inequable values for predicting single-agent chemoresistance.The purpose of this study is therefore to evaluate the efficacy of risk factors in predicting single-agent chemoresistance and explore the feasibility of simplifying the FIGO 2000 scoring system for GTN.Methods The clinical data of 578 GTN patients who received chemotherapy between January 2000 and December 2018 were retrospectively reviewed.Univariate and multivariate logistic regression analyses were carried out to identify risk factors associated with single-agent chemoresistance in low-risk GTN patients.Then,simplified models were built and compared with the original FIGO 2000 scoring system.Results Among the eight FIGO risk factors,the univariate and multivariate analyses identified that pretreatment serum human chorionic gonadotropin(hCG)level and interval from antecedent pregnancy were consistently independent predictors for both first-line and subsequent single-agent chemoresistance.The simplified model with two independent factors showed a better performance in predicting single-agent chemoresistance than the model with the other four non-independent factors.However,the addition of other co-factors did improve the efficiency.Overall,simplified models can achieve favorable performance,but the original FIGO 2000 prognostic system still features the highest discrimination.Conclusions Pretreatment serum hCG level and interval from antecedent pregnancy were independent predictors for both first-line and subsequent single-agent chemoresistance,and they had greater weight than other non-independent factors in predicting single-agent chemoresistance.The simplified model composed of certain selected factors is a promising alternative to the original FIGO 2000 prognostic system,and it shows comparable performance. 展开更多
关键词 Gestational trophoblastic neoplasia(GTN) Single-agent chemotherapy CHEMORESISTANCE Risk factor
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部